Exact Sciences (EXAS) reported $3.2B in revenue for fiscal 2025, +17.7% year on year. That ranks #1042 by revenue among 2853 SEC filers and #89 in Healthcare. It posted a net loss of −$208M for the same year. Revenue has grown 60.9% a year on average since 2011 ($4.2M then). The fiscal 2025 balance sheet shows $5.9B in total assets, $956M in cash and $50.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.2B | +17.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $2.3B | +17.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$206M | +$842M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$208M | +$821M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $491M | +133.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $135M | −1.0% | FY20252025-12-31 |
| Total assetsAssets | $5.9B | −1.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $2.4B | −0.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $956M | +59.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $50.0M | +110.5% | FY20232023-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 134 of 161 companies compared | −6.4% | |
| Operating marginRank 141 of 160 companies compared | −6.4% | |
| R&D as share of revenueRank 35 of 102 companies compared | 16.1% | |
| Cash as share of revenueRank 26 of 160 companies compared | 29.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Exact Sciences Corp
- Ticker
- EXAS
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001124140
Filings
- 10-KFeb 13, 2026Open filing →
- 10-QNov 3, 2025Open filing →
- 10-QAug 6, 2025Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Dentsply SironaXRAY | $3.7B | −$598M |
| Acadia HealthcareACHC | $3.3B | −$1.1B |
| Surgery PartnersSGRY | $3.3B | −$77.9M |
| Exact SciencesEXAS | $3.2B | −$208M |
| AdapthealthAHCO | $3.2B | −$70.8M |
| BiontechBNTX | $3.2B | −$1.3B |
| Biomarin PharmaceuticalBMRN | $3.2B | $349M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Exact Sciences — Key figures |url=https://companiesranked.com/en/company/exact-sciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Exact Sciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/exact-sciencesBibTeX
@misc{companiesranked-en-company-exact-sciences-2026,
author = {{CompaniesRanked}},
title = {{Exact Sciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/exact-sciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001124140-26-000011 · February 13, 2026
{{cite web |title=Exact Sciences — Key figures — 10-K (0001124140-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1124140/000112414026000011/exas-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.